The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Antisense technology: A review
Open accessAbstract
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are used in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow, and the field has been subject to a significant number of reviews. In this review, we focus on the molecular events that result in the effects observed and use recent clinical results involving several different ASOs to exemplify specific molecular mechanisms and specific issues. We conclude with the prospective on the technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Monoclonal Antibodies: Principles and Practice
Goding, J. W. (1996) · Cited by 942
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationTargeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W.-L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.09.007 · Cited by 629
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 4×
“The major advances here are focused primarily on PS ASOs and have included insights into the mechanisms of cellular uptake anddistribution, pharmacodynamics, and cellular and organ toxicity, and these in turn have resulted in new approaches to enhance the performance of PS ASOs (1, 3, 4, 37, 38).”
BackgroundInfluentialSelf-citationTherapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 574
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Self-citationPhase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565 · cited 2×
“This is an open access article under the CC Table 1 Clinical development activities of antisense medicines A - approved RNA targeted drugs Drug Indication Target RNA Mechanism Chemistry Year approved Fomivirsen Cytomegalovirus retinitis HCMV UL122 RNase H1 PS, DNA 1998 Mipomersen Homozygous familial hypercholesterolem…”
BackgroundFox, A. H., Lam, Y. W., Leung, A. K. L., Lyon, C. E., Andersen, J., Mann, M., & Lamond, A. I. (2002) · Current Biology · doi:10.1016/s0960-9822(01)00632-7 · Cited by 540
Gene Expression Regulation by Upstream Open Reading Frames and Human Disease
Barbosa, C., Peixeiro, I., & Romão, L. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003529 · Cited by 525
Entering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Self-citationTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Self-citationMonia, B. P., Johnston, J. F., Geiger, T., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
Monteleone, G., Neurath, M. F., Ardizzone, S., Di Sabatino, A., Fantini, M. C., Castiglione, F., Scribano, M. L., Armuzzi, A., Caprioli, F., Sturniolo, G. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407250 · Cited by 401
Molecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 396
Self-citationPhosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Self-citationMolecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H. M., & Prior, T. W. (2002) · Genetics in Medicine · doi:10.1097/00125817-200201000-00004 · Cited by 364
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Self-citationShen, W., De Hoyos, C. L., Migawa, M. T., Vickers, T. A., Sun, H., Low, A., Bell, T. A., Rahdar, M., Mukhopadhyay, S., Hart, C. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0106-2 · Cited by 345
Self-citationEnhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Self-citationIncreased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
Next-Generation Sequencing Technologies
McCombie, W. R., McPherson, J. D., & Mardis, E. R. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036798 · Cited by 308
Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
Liang, X.-H., Sun, H., Nichols, J. G., & Crooke, S. T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.002 · Cited by 292
Self-citationGaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279
Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 278
Self-citationNair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278
The Discovery of Insulin: An Important Milestone in the History of Medicine
Vecchio, I., Tornali, C., Bragazzi, N. L., & Martini, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00613 · Cited by 272
Antisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Self-citationReilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Locked nucleic acid: modality, diversity, and drug discovery
Hagedorn, P. H., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller, M. R., Papargyri, N., Christiansen, H., Hansen, B. R., et al. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.018 · Cited by 238
Discovery and development of new antibacterial drugs: learning from experience?
Jackson, N., Czaplewski, L., & Piddock, L. J. V. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky019 · Cited by 238
Changeux, J.-P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.407668 · Cited by 234
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Burel, S. A., Hart, C. E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.-H., Younis, H., Sabripour, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1210 · Cited by 216
Self-citationCurrent Development of siRNA Bioconjugates: From Research to the Clinic
Chernikov, I. V., Vlassov, V. V., & Chernolovskaya, E. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00444 · Cited by 216
Liang, X.-H., Shen, W., Sun, H., Migawa, M. T., Vickers, T. A., & Crooke, S. T. (2016) · Nature Biotechnology · doi:10.1038/nbt.3589 · Cited by 212
Self-citationZhang, H., Löwenberg, E. C., Crosby, J. R., MacLeod, A. R., Zhao, C., Gao, D., Black, C., Revenko, A. S., Meijers, J. C. M., Stroes, E. S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277798 · Cited by 203
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
van der Ree, M. H., van der Meer, A. J., de Bruijne, J., Maan, R., van Vliet, A., Welzel, T. M., Zeuzem, S., Lawitz, E. J., Rodriguez-Torres, M., Kupcova, V., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.08.015 · Cited by 199
Unique Gene‐Silencing and Structural Properties of 2′‐Fluoro‐Modified siRNAs
Manoharan, M., Akinc, A., Pandey, R. K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M. A., Nechev, L., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006519 · Cited by 193
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E.-M., Valeur, E., Jansson-Löfmark, R., Janzén, D., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 188
Liang, X.-H., Sun, H., Shen, W., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv143 · Cited by 182
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
Miller, C. M., Donner, A. J., Blank, E. E., Egger, A. W., Kellar, B. M., Østergaard, M. E., Seth, P. P., & Harris, E. N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw112 · Cited by 171
Tanowitz, M., Hettrick, L. A., Revenko, A. S., Kinberger, G. A., Prakash, T. P., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx960 · Cited by 165
Østergaard, M. E., Southwell, A. L., Kordasiewicz, H., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K., Villanueva, E. B., Swayze, E. E., Frank Bennett, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt725 · Cited by 163
RNA toxicity in non‐coding repeat expansion disorders
Swinnen, B., Robberecht, W., & Van Den Bosch, L. (2020) · The EMBO Journal · doi:10.15252/embj.2018101112 · Cited by 163
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Prakash, T. P., Mullick, A. E., Lee, R. G., Yu, J., Yeh, S. T., Low, A., Chappell, A. E., Østergaard, M. E., Murray, S., Gaus, H. J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz354 · Cited by 162
Gaus, H. J., Gupta, R., Chappell, A. E., Østergaard, M. E., Swayze, E. E., & Seth, P. P. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1260 · Cited by 160
Properties of Cloned and Expressed Human RNase H1
Wu, H., Lima, W. F., & Crooke, S. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28270 · Cited by 159
Self-citationLiang, X., Sun, H., Shen, W., Wang, S., Yao, J., Migawa, M. T., Bui, H., Damle, S. S., Riney, S., Graham, M. J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx632 · Cited by 158
Self-citationAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 139
Self-citation“Antisense Drug Technology. Principles, Strategies, and Applications”
Lee, G. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00090-5 · Cited by 135
Miner, P. B., Wedel, M. K., Bane, B. L., & Bradley, J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01863.x · Cited by 133
Crooke, S. T., Baker, B. F., Kwoh, T. J., Cheng, W., Schulz, D. J., Xia, S., Salgado, N. R., Bui, H., Hart, C. E., Burel, S. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.136 · Cited by 133
Self-citationMigawa, M. T., Shen, W., Wan, W. B., Vasquez, G., Oestergaard, M. E., Low, A., Hoyos, C. L. D., Gupta, R., Murray, S., Tanowitz, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz247 · Cited by 133
Self-citationWan, W. B., Migawa, M. T., Vasquez, G., Murray, H. M., Nichols, J. G., Gaus, H. J., Berdeja, A., Lee, S. S., Hart, C. E., Lima, W. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1115 · Cited by 132
Fred Saad, C., Hotte, S. J., North, S. A., Eigl, B. J., Chi, K., Czaykowski, P., Wood, L. A., Pollak, M., Berry, S. R., Lattouf, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0859 · Cited by 132
Fully modified 2' MOE oligonucleotides redirect polyadenylation
Vickers, T. A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.6.1293 · Cited by 132
Crooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 131
Self-citationCrooke, S. T., Baker, B. F., Witztum, J. L., Kwoh, T. J., Pham, N. C., Salgado, N., McEvoy, B. W., Cheng, W., Hughes, S. G., Bhanot, S., et al. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0650 · Cited by 129 · cited 5×
“Some occur acutely while others are observed only with repeated chronic administration (3, 25, 55, 56, 82, 177)”
BackgroundInfluentialSelf-citationThe emergence of the drug receptor theory
Maehle, A.-H., Prüll, C.-R., & Halliwell, R. F. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd875 · Cited by 128
Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0753 · Cited by 127
Self-citationOral Delivery of Antisense Oligonucleotides in Man
Tillman, L., Geary, R. S., & Hardee, G. E. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21084 · Cited by 127
Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells
Kotula, J. W., Pratico, E. D., Ming, X., Nakagawa, O., Juliano, R. L., & Sullenger, B. A. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0347 · Cited by 124
Sewell, K. L., Geary, R. S., Baker, B. F., Glover, J., Mant, T., Yu, R. Z., Tami, J. A., & Dorr, F. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036749 · Cited by 121
Self-citationØstergaard, M. E., Jackson, M., Low, A., Chappell, A. E., Lee, R. G., Peralta, R. Q., Yu, J., Kinberger, G. A., Dan, A., Carty, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz360 · Cited by 118
Loomba, R. S., Morgan, E. S., Watts, L. M., Xia, S., Hannan, L. A., Geary, R. S., Baker, B. F., & Bhanot, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30186-2 · Cited by 118
Self-citationShen, W., Hoyos, C. L. D., Sun, H., Vickers, T. A., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky060 · Cited by 115
Self-citationAntisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 115
Self-citationJudge, D. P., Kristen, A. V., Grogan, M. A., Maurer, M. S., Falk, R. H., Hanna, M. A., Gillmore, J. D., Garg, P. P., Vaishnaw, A. K., Harrop, J., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06919-4 · Cited by 115
Koziołkiewicz, M., Krakowiak, A., Kwinkowski, M., Boczkowska, M., & Stec, W. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5000 · Cited by 111
2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
Shen, W., Liang, X., Sun, H., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv298 · Cited by 111
Self-citationJahns, H., Roos, M. M., Imig, J., Baumann, F., Wang, Y., Gilmour, R., & Hall, J. (2015) · Nature Communications · doi:10.1038/ncomms7317 · Cited by 109
Chi, K. N., Yu, E. Y., Jacobs, C. A., Bazov, J., Kollmannsberger, C., Higano, C. S., Mukherjee, S. D., Gleave, M. E., STEWART, P. S., & Hotte, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw068 · Cited by 109
A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy
Wu, X., Wang, S., Sun, J., Krainer, A. R., Hua, Y., & Prior, T. W. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx166 · Cited by 108
Lima, W. F., Murray, H. M., Damle, S. S., Hart, C. E., Hung, G., Hoyos, C. L. D., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw350 · Cited by 107
Self-citationMiner, P. B., Wedel, M. K., Xia, S., & Baker, B. F. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02837.x · Cited by 104
Self-citationSuzuki, Y., Holmes, J. B., Cerritelli, S. M., Sakhuja, K., Minczuk, M. A., Holt, I. J., & Crouch, R. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00619-10 · Cited by 104
Phosphorothioate oligonucleotides can displaceNEAT1RNA and form nuclear paraspeckle-like structures
Shen, W., Liang, X., & Crooke, S. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku579 · Cited by 103
Self-citationØstergaard, M. E., Hoyos, C. L. D., Wan, W. B., Shen, W., Low, A., Berdeja, A., Vasquez, G., Murray, S., Migawa, M. T., Liang, X., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa031 · Cited by 101
Self-citationOka, N., Wada, T., & Saigo, K. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034502z · Cited by 98
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Sands, B. E., Feagan, B. G., Sandborn, W. J., Schreiber, S., Peyrin‐Biroulet, L., Colombel, J., Rossiter, G., Usiskin, K., Ather, S., Zhan, X., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000493 · Cited by 98
Goemans, N., Tulinius, M., van den Hauwe, M., Kroksmark, A., Buyse, G., Wilson, R. J., van Deutekom, J. C., de Kimpe, S. J., Lourbakos, A., & Campion, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161955 · Cited by 96
Koziołkiewicz, M., Wójcik, M., Kobylańska, A., Karwowski, B. T., Rębowska, B., Guga, P., & Stec, W. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.43 · Cited by 96
Anti-Inflammatory Activity of Inhaled IL-4 Receptor-α Antisense Oligonucleotide in Mice
Karras, J. G., Crosby, J. R., Guha, M., Tung, D., Miller, D. A., Gaarde, W. A., Geary, R. S., Monia, B. P., & Gregory, S. A. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0456oc · Cited by 95
Khan, N., Eliopoulos, H., Han, L., Kinane, T. B., Lowes, L. P., Mendell, J. R., Gordish‐Dressman, H., Henricson, E., McDonald, C. M., & on behalf of the Eteplirsen Investigators and the CINRG DNHS Investigators (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180351 · Cited by 95
Bianchini, D., Omlin, A. G., Pezaro, C. J., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.619 · Cited by 94
Liang, X., Shen, W., Sun, H., Prakash, T. P., & Crooke, S. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku484 · Cited by 94
Self-citationMaehle, A. (2004) · Medical History · doi:10.1017/s0025727300000090 · Cited by 94
Investigating the Structure of Human RNase H1 by Site-directed Mutagenesis
Wu, H., Lima, W. F., & Crooke, S. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009676200 · Cited by 92
Self-citationLima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Siwkowski, A. M., & Crooke, S. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025015 · Cited by 89
Self-citationSenn, J. J., Burel, S. A., & Henry, S. P. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084004 · Cited by 88
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Janas, M. M., Zlatev, I., Liu, J., Jiang, Y., Barros, S. A., Sutherland, J. E., Davis, W. P., Liu, J., Brown, C. R., Liu, X., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz140 · Cited by 88
Vickers, T. A., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv920 · Cited by 87
Self-citationLong-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L. H., Donoghue, C., Dracker, R. A., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., et al. (2019) · Medicine · doi:10.1097/md.0000000000015858 · Cited by 85
Lima, W. F., Nichols, J. G., Wu, H., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405035200 · Cited by 83
Self-citationEfficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice
Liang, X., Vickers, T. A., Guo, S., & Crooke, S. T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1121 · Cited by 82
Self-citationCastanotto, D., Lin, M., Kowolik, C. M., Wang, L., Ren, X., Soifer, H. S., Koch, T., Hansen, B. R., Oerum, H., Armstrong, B., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv964 · Cited by 82
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
Cohn, D. M., Viney, N. J., Fijen, L. M., Schneider, E., Alexander, V. J., Xia, S., Kaeser, G. E., Nanavati, C., Baker, B. F., Geary, R. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915035 · Cited by 80
Self-citationLiang, X., Shen, W., Sun, H., Kinberger, G. A., Prakash, T. P., Nichols, J. G., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw144 · Cited by 79
Self-citationAnnexin A2 facilitates endocytic trafficking of antisense oligonucleotides
Wang, S., Sun, H., Tanowitz, M., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw595 · Cited by 77
Self-citationLima, W. F., Hoyos, C. L. D., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw065 · Cited by 75
Self-citationWang, S., Allen, N., Vickers, T. A., Revenko, A. S., Sun, H., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky145 · Cited by 75
Self-citationDevelopment of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions
Vickers, T. A., & Crooke, S. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161930 · Cited by 74
Self-citationPfeiffer, N., Voykov, B., Renieri, G., Bell, K. C., Richter, P., Weigel, M., Thieme, H., Wilhelm, B., Lorenz, K., Feindor, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188899 · Cited by 73
Vickers, T. A., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108625 · Cited by 72
Self-citationLipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
Wang, S., Allen, N., Prakash, T. P., Liang, X., & Crooke, S. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0794 · Cited by 72
Self-citation100 years of modelling ligand–receptor binding and response: A focus on GPCRs
Finlay, D. B., Duffull, S. B., & Glass, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14988 · Cited by 72
Kandimalla, E. R., Bhagat, L., Wang, D., Yu, D. S., Sullivan, T., Monica, N. L., & Agrawal, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt078 · Cited by 71
Bailey, J., Shen, W., Liang, X., & Crooke, S. T. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx709 · Cited by 70
Self-citationTherapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Tang, X., Zhang, S., Fu, R., Zhang, L., Huang, K., Peng, H., Dai, L., & Chen, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01208 · Cited by 69
The Effects of 2′- O -Methoxyethyl Oligonucleotides on Renal Function in Humans
Crooke, S. T., Baker, B. F., Pham, N. C., Hughes, S. G., Kwoh, T. J., Cai, D., Tsimikas, S., Geary, R. S., & Bhanot, S. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0693 · Cited by 69
Self-citationGrillone, L. R., & Lanz, R. (2001) · Drugs of today · doi:10.1358/dot.2001.37.4.620590 · Cited by 69
The impact of base stacking on the conformations and electrostatics of single-stranded DNA
Plumridge, A., Meisburger, S. P., Andresen, K., & Pollack, L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx140 · Cited by 65
Weidner, D. A., Valdez, B. C., Henning, D., Greenberg, S. R., & Busch, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00517-d · Cited by 63
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
MacLeod, A. R., & Crooke, S. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.957 · Cited by 63
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.001 · Cited by 63
Self-citationAbdul-Manan, N., & Williams, K. R. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.20.4063 · Cited by 62
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Liang, X., Nichols, J. G., Hsu, C., Vickers, T. A., & Crooke, S. T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz500 · Cited by 62
Self-citationCOMBREX: a project to accelerate the functional annotation of prokaryotic genomes
Roberts, R. J., Chang, Y.-C., Hu, Z., Rachlin, J., Anton, B. P., Pokrzywa, R. M., Choi, H.-P., Faller, L. L., Guleria, J., Housman, G., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1168 · Cited by 61
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
Limmroth, V., Barkhof, F., Desem, N., Diamond, M. P., Tachas, G., & For the ATL1102 Study Group (2014) · Neurology · doi:10.1212/wnl.0000000000000926 · Cited by 58
Zanardi, T. A., Han, S.-C., Jeong, E. J., Rime, S., Yu, R. Z., Chakravarty, K., & Henry, S. P. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197426 · Cited by 56
Molecular Cloning and Expression of cDNA for Human RNase H
Wu, H., Lima, W. F., & Crooke, S. T. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.53 · Cited by 56
Self-citationWerten, S., Langen, F. W. M., van Schaik, R. F. M. A., Timmers, H. T. M., Meisterernst, M., & van der Vliet, P. C. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1534 · Cited by 55
Morgan, E. S., Tai, L.-J., Pham, N. C., Overman, J. K., Watts, L. M., Smith, A. V., Jung, S. W., Gajdošík, M., Krššák, M., Krebs, M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1343 · Cited by 53
Self-citationJudge, D. P., Kristen, A. V., Grogan, M. A., Maurer, M. S., Falk, R. H., Hanna, M. A., Gillmore, J. D., Garg, P. P., Vaishnaw, A. K., Harrop, J., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07023-8 · Cited by 51
Liang, X., Hart, C. E., & Crooke, S. T. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.01.011 · Cited by 50
Self-citationMechanisms of Antisense Drug Action, an Introduction
Vickers, T., Wu, H., Crooke, S., & Lima, W. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-7 · Cited by 49
Self-citationLiang, X., Sun, H., Hsu, C., Nichols, J. G., Vickers, T. A., Hoyos, C. L. D., & Crooke, S. T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1171 · Cited by 49
Self-citationDefining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
Lima, W. F., Vickers, T. A., Nichols, J. G., Li, C., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101752 · Cited by 48
Self-citationA global transcription cofactor bound to juxtaposed strands of unwound DNA
Werten, S., & Moras, D. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1044 · Cited by 48
Hodges, D., & Crooke, S. T. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10549-x · Cited by 48
Self-citationDIGENIO, A. G., Pham, N. C., Watts, L. M., Morgan, E. S., Jung, S. W., Baker, B. F., Geary, R. S., & Bhanot, S. (2018) · Diabetes Care · doi:10.2337/dc17-2132 · Cited by 47
Self-citationLiang, X., Sun, H., Nichols, J. G., Allen, N., Wang, S., Vickers, T. A., Shen, W., Hsu, C., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky841 · Cited by 44
Self-citationKinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
Vickers, T. A., Rahdar, M., Prakash, T. P., & Crooke, S. T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz771 · Cited by 43
Self-citationLima, W. F., Wu, H., Nichols, J. G., Prakash, T. P., Ravikumar, V. T., & Crooke, S. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306543200 · Cited by 41
Self-citationTrainer, P. J., Newell-Price, J. D. C., Ayuk, J., Aylwin, S. J. B., Rees, A., Drake, W. M., Chanson, P., Brue, T. C., Webb, S. M., Fajardo, C., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0138 · Cited by 40
Størling, Z. M., & Koch, T. (2008) · Wiley eBooks · doi:10.1002/9780470048672.wecb516 · Cited by 39
Lima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Vasquez, G., Swayze, E. E., & Crooke, S. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025429 · Cited by 39
Self-citationIONIS-PKK Rx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
Ferrone, J. D., Bhattacharjee, G., Revenko, A. S., Zanardi, T. A., Warren, M. S., Derosier, F. J., Viney, N. J., Pham, N. C., Kaeser, G. E., Baker, B. F., et al. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0754 · Cited by 39
Self-citationVickers, T. A., Lima, W. F., Wu, H., Nichols, J. G., Linsley, P. S., & Crooke, S. T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp735 · Cited by 37
Self-citationToxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man
Henry, S. P., Kim, T., Kramer-Stickland, K., Zanardi, T. A., Fey, R. A., & Levin, A. A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-20 · Cited by 37
Transcriptomic analysis of the role of RasGEF1B circular RNA in the TLR4/LPS pathway
Ng, W. L., Marinov, G. K., Chin, Y., Lim, Y., & Ea, C.-K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12550-w · Cited by 37
Discovery of Innovative Small Molecule Therapeutics
Abou-Gharbia, M. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8012823 · Cited by 34
Effect of ion pairing on bond order and charge localization in alkyl phosphorothioates
Baraniak, J., & Frey, P. A. (1988) · Journal of the American Chemical Society · doi:10.1021/ja00220a067 · Cited by 34
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Kennedy, B. W. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1504845 · Cited by 34
Geary, R. S., Yu, R. Z., Siwkowski, A., et al. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-19 · Cited by 32
Fey, R. A., Templin, M. V., McDonald, J. D., Yu, R. Z., Hutt, J. A., Gigliotti, A. P., Henry, S. P., & Reed, M. D. (2014) · Inhalation Toxicology · doi:10.3109/08958378.2014.907587 · Cited by 31
Shen, W., Liang, X., Sun, H., Hoyos, C. L. D., & Crooke, S. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173494 · Cited by 31
Self-citationAlicaforsen for the treatment of inflammatory bowel disease
Jairath, V., Khanna, R., & Feagan, B. G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1349753 · Cited by 31
Querfeld, C., Foss, F. M., Pinter‐Brown, L. C., Porcu, P., William, B. M., Pacheco, T. R., Haverkos, B. M., Kim, Y. H., Guitart, J., Halwani, A. S., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.820.820 · Cited by 31
Flaim, J., Grundy, J. S., Baker, B. F., McGowan, M. P., & Kastelein, J. J. P. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000560 · Cited by 29
Self-citationNarayanan, P., Curtis, B. R., Shen, L., Schneider, E., Tami, J. A., Paz, S., Burel, S. A., Tai, L.-J., Machemer, T., Kwoh, T. J., et al. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0829 · Cited by 29
Paz, S., Hsiao, J., Cauntay, P., Soriano, A., Bai, L., Machemer, T., Xiao, X., Guo, S., Hung, G., Younis, H. S., et al. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0668 · Cited by 28
Lima, W. F., Wu, H., & Crooke, S. T. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-8 · Cited by 27
Self-citationHydration of single-stranded phosphodiester and phosphorothioate oligodeoxyribonucleotides
White, A. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.16.3261 · Cited by 26
The Medicinal Chemistry of Oligonucleotides
Swayze, E. E., & Bhat, B. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-13 · Cited by 26
Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
Liang, X., Nichols, J. G., Sun, H., & Crooke, S. T. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1174 · Cited by 25
Self-citationZhao, C., Crosby, J. R., Lv, T., Bai, D., Monia, B. P., & Guo, S. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.07.006 · Cited by 24
Grossman, T. R., Carrer, M., Shen, L., Johnson, R. B., Hettrick, L. A., Henry, S. P., Monia, B. P., & McCaleb, M. L. (2017) · PubMed Central · Cited by 24
Liang, X., Nichols, J. G., Hoyos, C. L. D., & Crooke, S. T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa715 · Cited by 24
Self-citationU1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP
Vickers, T. A., Sabripour, M., & Crooke, S. T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr150 · Cited by 23
Self-citationRenal Effects of Antisense-Mediated Inhibition of SGLT2
van Meer, L., Moerland, M., van Dongen, M., Goulouze, B., de Kam, M., Klaassen, E. S., Cohen, A. F., & Burggraaf, J. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233809 · Cited by 21
Substitution of tryptophan 89 with tyrosine switches the DNA binding mode of PC4
Huang, J., Zhao, Y., Liu, H., Huang, D. Y., Cheng, X., Zhao, W., Taylor, I. A., Liu, J., & Peng, Y. (2015) · Scientific Reports · doi:10.1038/srep08789 · Cited by 20
Wang, S., Allen, N., Liang, X., & Crooke, S. T. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.10.011 · Cited by 20
Self-citationFactor XI Antisense Oligonucleotide for Venous Thrombosis
Gupta, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1503223 · Cited by 19
Vickers, T. A., Freier, S. M., Bui, H., Watt, A. T., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110615 · Cited by 16
Self-citationChowdhury, S. K., Burris, H. A., Patel, M., Infante, J. R., Jones, S. F., Voskoboynik, M., Parry, K., Elvin, P., Coleman, T., Gardner, H., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)33031-3 · Cited by 16
Steinke, C. A., Reeves, K. K., Powell, J. W., Lee, S. A., Chen, Y., Wyrzykiewicz, T. K., Griffey, R. H., & Mohan, V. (1997) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.1997.10508149 · Cited by 15
Basic Principles of Antisense Drug Discovery
Freier, S. M., & Watt, A. T. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-12 · Cited by 14
Cited by
Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities
Gabriele, R. M. C., Abel, E., Fox, N. C., Wray, S., & Arber, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.835645 · Cited by 44
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching
Dawicki-McKenna, J. M., Felix, A. J., Waxman, E. A., Cheng, C., Amado, D. A., Ranum, P. T., Bogush, A., Dungan, L. V., Maguire, J. A., Gagne, A. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38273-3 · Cited by 41
Wu, A.-X., Wang, X.-J., Zhao, C., Hu, J.-Q., Li, J.-W., Xu, Y., Li, Y., & Liu, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108178 · Cited by 1
Metadata
- Authors
- Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 296
- Pages
- 100416
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3131848822
- Cited by
- 326
- References
- 211
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.